The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
There are currently 22 open trials.
In 107 locations
What is a Clinical Trial?
There are currently 22 open trials
- Teclistamab for relapsed and refractory myeloma
- JNJ-68284528 CART-cell therapy for relapsed and refractory myeloma
- Belantamab mafodotin with bortezomib, lenalidomide and dexamethasone for newly diagnosed myeloma (DREAMM 9)
- Adaptive treatment in newly diagnosed myeloma patients not eligible for HDT-SCT (FiTNEss, Myeloma XIV)
- Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
- Belantamab mafodotin in combination with bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-7)
- Belantamab mafodotin versus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-3)
- A clinical trial evaluating RO5126766 for the treatment of refractory myeloma patients
- Understanding bone pain in myeloma
- Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
- CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Using diffusion weighted MRI to measure myeloma disease burden and bone loss (LOOMIS)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- CC-92480 for relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Observational evaluation of myeloma patients (PREAMBLE)
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
Teclistamab for relapsed and refractory myeloma
Treatments:
Teclistamab
Myeloma stage:
Relapsed, Refractory
Trial phase:
II
Summary:
This trial is investigating whether a drug called teclistamab is safe and effective for the treatment of relapsed and/or refractory myeloma patients.
Teclistamab is is a new type of immunotherapy called a bispecific antibody. It works by helping your T-cells (a type of immune cells) find and kill myeloma cells.
Locations:
University College Hospital, London;
The Royal Marsden Hospital, Sutton
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have received at least three lines of treatment including an immunomodulatory drug (e.g. lenalidomide (Revlimid)), a proteasome inhibitor (e.g. bortezomib (Velcade)) and an anti-CD38 monoclonal antibody (e.g. daratumumab (Darzalex)).
What's involved?:
Patients will be given teclistamab subcutaneously (injection into the skin).
Patients will be required to attend outpatient clinics for regular check-ups and blood tests.
Clinical Information
(for Medical Professionals):
A Phase II, open-label clinical trial evaluating the safety and efficacy of teclistamab for relapsed and/or refractory myeloma.
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk